TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05064683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: white noise
Description: Newborns in the control group did not receive any treatment other than routine applications while receiving nasal CPAP support in the neonatal intensive care unit.The newborns in the faciliated tucking group were given supine, prone, and lateral positions for 24 hours, depending on their clinical status.The newborns in the white noise group were listened to white noise for 24 hours using an Mp3 player and a decibel measuring device to measure the sound level.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: white noise
Description: Newborns in the control group did not receive any treatment other than routine applications while receiving nasal CPAP support in the neonatal intensive care unit.The newborns in the faciliated tucking group were given supine, prone, and lateral positions for 24 hours, depending on their clinical status.The newborns in the white noise group were listened to white noise for 24 hours using an Mp3 player and a decibel measuring device to measure the sound level.
Study: NCT05665465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray 0.5 mg
Description: Participants will be administered nicotine nasal spray and provide subjective reactions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray 0.5 mg
Description: Participants will be administered nicotine nasal spray and provide subjective reactions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be administered placebo nasal spray and provide subjective reactions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be administered placebo nasal spray and provide subjective reactions
Study: NCT04952454

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: External Dacryocystorhinostomy
Description: The resistance of the lacrimal drainage is lowered by creating a new ostium between the lacrimal sac and nasal cavity via skin incision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endonasal Dacryocystorhinostomy
Description: The resistance of the lacrimal drainage is lowered by creating a new ostium between the lacrimal sac and nasal cavity via endonasal route.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcanalicular Dacryocystorhinostomy
Description: The resistance of the lacrimal drainage is lowered by creating a new ostium between the lacrimal sac and nasal cavity via transcanalicular route.
Study: NCT06587971

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oral hygiene education
Description: Providing guidance on proper brushing techniques, smoking cessation, dietary control, and blood sugar management.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Oral hygiene education
Description: Providing guidance on proper brushing techniques, smoking cessation, dietary control, and blood sugar management.
Study: NCT06597305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Twenty Session Cognitive-Behavioral Therapy for Anorexia Nervosa (CBT-20-AN)
Description: Twenty session cognitive behavioral therapy for Anorexia Nervosa (CBT-20-AN) is an treatment for Anorexia Nervosa delivered by a mental health clinician. This treatment (CBT-20-AN) lasts just 20 sessions and has been designed to allow individuals with AN to reap the benefits of CBT for eating disorders (up to 40 sessions) in less time, increasing access to care and shortening time to symptom reduction.
Study: NCT06597188

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitaFlow Liberty
Description: All subjects randomized to the TAVR group will receive transcatheter aortic valve replacement (TAVR) with the study device of VitaFlow Liberty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Commercially available surgical bioprosthetic valve
Description: All subjects randomized to the SAVR group will receive surgical aortic valve replacement (SAVR) with the control device of a commercially available surgical bioprosthetic valve.
Study: NCT06586645

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety Planning
Description: Safety planning is a standard suicide risk assessment and management protocol. This protocol involves determining level of risk based on current and prior suicidal thoughts and behavior, and then collaborative planning with youth and families for self-monitoring, self-regulation, help seeking, and suicide means restriction.
Study: NCT06151223

Intervention type: OTHER
Intervention: Bio-specimen Collection: Blood
Description: At study enrollment and prior to any pancreatic surgery and prior to or at least 3 days after the most recent GI endoscopy procedure, approximately 50 ml (10 teaspoons) of blood will be drawn from all participants and be processed according to standardized study biospecimen protocol. Serial blood collection will be offered to all the participants depending on the subjects' tier classification. Blood draw will be completed at Mayo Clinic when the subjects come back, or study blood draw kit may be sent for external collection.
Study: NCT06586645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Planning
Description: Safety planning is a standard suicide risk assessment and management protocol. This protocol involves determining level of risk based on current and prior suicidal thoughts and behavior, and then collaborative planning with youth and families for self-monitoring, self-regulation, help seeking, and suicide means restriction.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Give to Others Module
Description: The Give to Others Module is a brief cognitive behavioral intervention targeting youth burden-related beliefs. It consists of one primary session and brief phone follow-up.
Study: NCT06596161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron sucrose
Description: Receving iron

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05727306

Intervention type: OTHER
Intervention: No intervention
Description: Observational analysis of usual care only.

Intervention type: OTHER
Intervention: No intervention
Description: Observational analysis of usual care only.
Study: NCT06151223

Intervention type: OTHER
Intervention: Bio-specimen Collection: Blood
Description: At study enrollment and prior to any pancreatic surgery and prior to or at least 3 days after the most recent GI endoscopy procedure, approximately 50 ml (10 teaspoons) of blood will be drawn from all participants and be processed according to standardized study biospecimen protocol. Serial blood collection will be offered to all the participants depending on the subjects' tier classification. Blood draw will be completed at Mayo Clinic when the subjects come back, or study blood draw kit may be sent for external collection.

Intervention type: OTHER
Intervention: Bio-specimen Collection: Pancreatic Juice
Description: This may be collected from research subjects every time they are undergoing a clinically indicated endoscopic ultrasound (EUS), endoscopic retrograde cholangiopancreatography (ERCP) or upper gastrointestinal endoscopy (EGD) procedure. Pancreatic juice will not be collected if PI or provider determines it is not in the best interest of the subject. Pancreatic juice collection will be performed prior to fine needle aspiration (FNA), brushing or stent placements if performed during the same endoscopic procedure.

Intervention type: OTHER
Intervention: Bio-specimen Collection: Pancreatic Juice
Description: This may be collected from research subjects every time they are undergoing a clinically indicated endoscopic ultrasound (EUS), endoscopic retrograde cholangiopancreatography (ERCP) or upper gastrointestinal endoscopy (EGD) procedure. Pancreatic juice will not be collected if PI or provider determines it is not in the best interest of the subject. Pancreatic juice collection will be performed prior to fine needle aspiration (FNA), brushing or stent placements if performed during the same endoscopic procedure.
Study: NCT05056415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Everyday Life Rehabilitation (ELR)
Description: Everyday Life Rehabilitation (ELR) is an intervention model for integrated occupational therapy in close collaboration with housing staff in sheltered and supported housing facilities (Lindström, 2007; 2011), aiming at personal recovery and engagement in meaningful everyday activities for persons with SPD. The mediators are: personcentred, motivational, recovery- and activity-based methods, negotiation of user goal priority and expected outcome; methods for training in real-life situations; devices for collaboration; support from staff on an everyday basis; and an educational package including web-sections, manuals, and collegiate tutorial.~The language and actions of professionals promote hope, self-discovery and shared-decision making, shaped in partnership with residents. The resident is also encouraged to access different resources outside of health and social care such as family, peer and social support, out-of-housing strategies, and sources in the open society.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: No standardized instructions about the efforts is given to staff at the accommodations. Usually, only short terms efforts are offered to residents, such as prescribing technical aids.
Study: NCT06596343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant Chemotherapy Combined with Traditional Chinese Medicine (TCM) Supportive Therapy
Description: 1. Chemotherapy Regimen:~   * Postoperative adjuvant chemotherapy: A dual-drug concurrent regimen will be used, with each cycle lasting 21 days. On day 1 of each cycle, oxaliplatin will be administered intravenously at a dose of 130 mg/m². From day 1 to day 14 of each cycle, capecitabine will be taken orally at a dose of 1000 mg/m², twice daily. The treatment duration will follow the CSCO 2023 guidelines for colorectal cancer, with chemotherapy lasting for 6 months.~2. TCM Treatment:~   * TCM treatment will be based on syndrome differentiation (Zheng) and guided by the Guidelines for TCM Diagnosis and Treatment of Malignant Tumors.
Study: NCT06588543

Intervention type: DEVICE
Intervention: Endovascular treatment
Description: Endovascular treatment

Intervention type: DEVICE
Intervention: Endovascular treatment
Description: Endovascular treatment
Study: NCT06598020

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Competency-based training purposed to alleviate anxiety relief using a mind-body modality and improve pain with touch modalities (e.g., acupressure)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Care
Description: Competency-based training purposed to alleviate anxiety relief using a mind-body modality and improve pain with touch modalities (e.g., acupressure)
Study: NCT06598280

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation with femoral closure using closing system
Description: The ablation procedure will be performed under deep sedation/general anaesthesia as standard of care. Vital signs will be monitored. For patients on oral anticoagulation, the procedure will be performed according to the latest guidelines. For catheter access, sheaths will be placed in the femoral veins after ultrasound-guided puncture according to institutional standard. If the patient is randomised to the SDD group prior to the procedure, the femoral access will be closed with a closure system. Ablation technique, number of access points and procedural details will be performed according to institutional standard. Patients may be enrolled regardless of the energy source used for ablation. The minimum procedural endpoint is PVI. Ablation strategies in addition to PVI are at the discretion of the operator. Antiarrhythmic therapy may be administered for a maximum of 2 months (blanking period).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation with femoral closure using figure-of-eight stitch
Description: The ablation procedure will be performed under deep sedation/general anaesthesia as standard of care. Vital signs will be monitored. For patients on oral anticoagulation, the procedure will be performed according to the latest guidelines. For catheter access, sheaths will be placed in the femoral veins after ultrasound-guided puncture according to institutional standard. If the patient is randomised to the ONS group prior to the procedure, the femoral access will be closed with a figure-of-eight suture. The ablation technique, number of access points and procedural details will be performed according to institutional standard. Patients may be enrolled regardless of the energy source used for ablation. The minimum procedural endpoint is PVI. Ablation strategies in addition to PVI are at the discretion of the operator. Antiarrhythmic therapy may be administered for a maximum of 2 months (blanking period).
Study: NCT06603428

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: internal fixation by plate or screws
Description: - Patients more than 5 ml displacement of GT fracture (3ml in active highly demanded patient) are for internal fixation, others less this are for conservative management.
Study: NCT06591091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clemastine Fumarate
Description: Listed in arm/group description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clemastine Fumarate
Description: Listed in arm/group description
Study: NCT06595199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online peer support
Description: A closed online peer support group
Study: NCT06589037

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: shock wave treatment control group
Description: The control group, consisting of 24 people, will receive shock wave treatment on the sole of the foot to treat plantar fasciitis. There will be 4 sessions and 4 data collections.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: shock wave treatment experimental group
Description: The experimental group, consisting of 24 people, will receive shockwave treatment on the back of the leg to treat plantar fasciitis. There will be 4 sessions and 4 data collections.
Study: NCT06604052

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduced-Port Fusion Surgery
Description: (1) The Joint Trocar/Stoma Zone will be delineated by the stoma therapist. (2) The placement of the fusion point will involve collaboration between the surgeon and stoma therapist. This will be based on the surgeon\&#39;s trocar placement plan and the stoma therapist\&#39;s positioning principles. (3) Follow the principles of modified stomal positioning. (4) The surgeon will insert the main trocar based on the preoperative positioning point. During stoma creation, the 12 mm main trocar incision will be extended to 25-30 mm to create an ileostomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional surgery
Description: (1) The stoma therapists perform stoma positioning using traditional stoma positioning method. The surgeon will determine the primary trocar location, ensuring it does not overlap with the stoma site. (2) The surgeon will insert the primary trocar based on the preoperative positioning point and conduct the surgery. During stoma creation, the surgeons create ileal stoma according to the preoperative stoma positioning point.
Study: NCT06599905

Intervention type: OTHER
Group type: OTHER
Intervention: Episodic Migraine (EM)
Description: Three stimulus offset trials (OT) and three constant temperature trials (CT) applied to the forehead based on the individual heat pain threshold (HPT).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Episodic Migraine (EM)
Description: Three stimulus offset trials (OT) and three constant temperature trials (CT) applied to the forehead based on the individual heat pain threshold (HPT).

Intervention type: OTHER
Group type: OTHER
Intervention: Chronic Migraine (CM)
Description: Three stimulus offset trials (OT) and three constant temperature trials (CT) applied to the forehead based on the individual heat pain threshold (HPT).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chronic Migraine (CM)
Description: Three stimulus offset trials (OT) and three constant temperature trials (CT) applied to the forehead based on the individual heat pain threshold (HPT).
Study: NCT05767749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine + epinephrine 1:100,000
Description: 0.5 ml lidocaine + epinephrine 1:100,000, buffered 1/10 with sodium bicarb.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine + epinephrine 1:100,000
Description: 0.5 ml lidocaine + epinephrine 1:100,000, buffered 1/10 with sodium bicarb.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% Injectable Solution
Description: 0.5 ml Ropivacaine 0.5% Injectable Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% Injectable Solution
Description: 0.5 ml Ropivacaine 0.5% Injectable Solution
Study: NCT06151223

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: A research MRI with contrast that includes a Magnetic Resonance Cholangiopancreatography (MRCP) will be offered to patients in the Tier 2 cohort at baseline and at 3-year intervals if not done as standard of care. Gadolinium based intravascular contrast will be administered for this procedure. Sedation for claustrophobia/anxiety per clinical protocol will be an option if the patients requested. Subject would be notified of any concerning results. A safety questionnaire will be completed by the study team before ordering the MRI.~Clinically indicated MRIs for the TIER 1 participants will be used and collected as part of the registry.~If a clinical MRI/MRCP has been performed between 0 to 3 months before obtaining consent, the prior clinical MRI/MRCP could be used to obtain baseline imaging data.
Study: NCT05830045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLP2117
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QLP2117
Description: Specified dose on specified days
Study: NCT04987086

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSMA PET
Description: PSMA PET may have influence on the clinical decision-making of the patients with renal cancer
Study: NCT05332145

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAP to Health
Description: In Phase 1, participants will complete the web-based interview and Aim 1 measures, assessing acceptability and usability of the intervention. The investigators will review whether the intervention appropriately gathers information needed to program theory-based, personalized text messages. After completing the measures, a list of text messages for that participant will be generated and sent to the participant for review. Participants will review the text messages and rate the extent to which the messages are personalized. In Phase 2, the investigators will conduct a proof-of-concept pilot trial in which participants will complete a 4-week pretest monitoring period and an 8-week pilot trial of the intervention, with assessments of Self-Determination Theory mechanisms and meaning salience at pretest (-4 weeks), baseline (0 weeks), midpoint (4 weeks) and posttest (8 weeks). In addition, participants will wear accelerometers to assess physical activity during the 12 weeks.
Study: NCT05169138

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Aromatherapy application /massage with lavender oil
Description: The application was applied to 37 pregnant women in total, and the effect of massage with lavender oil on labor pain was investigated.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Aromatherapy application / inhalation with lavender oil
Description: The application was applied to 41 pregnant women in total, and the effect of inhalation with lavender oil on labor pain was investigated.
Study: NCT05425628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeoChord Transcatheter Mitral Repair System (or NeoChord System)
Description: The NeoChord Transcatheter Mitral Repair System is a system of delivery devices and implantable Neochordae and Anchor. The system is designed to percutaneously deliver and deploy the implantable ePTFE sutures, Neochordae as artificial chordae at the mitral valve and connect them to the implantable ventricular anchor, Anchor, using a catheter based system placed into the left side of the heart through the interatrial septum.
Study: NCT05767749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% Injectable Solution
Description: 0.5ml bupivacaine 0.5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% Injectable Solution
Description: 0.5ml bupivacaine 0.5%
Study: NCT05173740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individually tailored rehabilitation intervention
Description: Individually tailored rehabilitation intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care
Study: NCT06057675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment (tranexamic acid and 1% lidocaine with 1:100,000 epinephrine)
Description: Subcutaneous injection of local anesthetic (1% lidocaine with 1:100,000 epinephrine) and tranexamic acid (1g/10mL), mixed in a 9:1 volume ratio.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control (1% lidocaine with 1:100,000 epinephrine)
Description: Subcutaneous injection of local anesthetic (1% lidocaine with 1:100,000 epinephrine)
Study: NCT06592872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bullying prevention
Description: The intervention utilizes a serious (educational) videogame and teacher-led, interactive class sessions. Students exposed to the intervention will learn to respond to in-person and online bullying from the perspectives of perpetrator, victim, and bystander. The intervention enhances personal self-management skills, social skills, refusal skills, and other life skills needed to successfully navigate developmental tasks, increase resilience, and facilitate healthy psychosocial development.
Study: NCT06599918

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinamide
Description: Administration of NAM on a variable dose depending on the participant's body weight. Administration is done orally, daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo on a variable dose depending on the participant's body weight. Administration is done orally, daily.
Study: NCT06587607

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VA Compassionate Awareness Learning Module (VA CALM) a mindfulness curriculum.
Description: VA CALM is a 9 week mindfulness curriculum typically delivered at a once/week module pace in group settings during sessions that last approximately 60-90 minutes. Module topics include: Program Introduction, Why mindfulness, Perception, What Makes Something a Pleasant Experience?, Being Stuck, Getting Unstuck, Communication, Mindfulness in Daily Life, and Today is the First Dat of the Rest of Your Life.